Centre directs tighter surveillance of GLP-1 drug promotion
The government told state and union territory drug regulators to strengthen oversight of GLP-1 weight-loss drugs after concerns about surrogate advertising and misleading awareness campaigns. Minister of State for Health Anupriya Patel said the CDSCO has approved GLP-1 receptor agonists only for type 2 diabetes and chronic weight management in adults with specified conditions, and they may be dispensed only on endocrinologist or internal medicine specialist prescription. CDSCO advisories on March 10 and March 27, 2026, barred surrogate promotion, ordered stricter supply-chain monitoring, and asked states to act against diversion and non-compliant advertisements under existing drug laws.
CDSCO barred surrogate ads and ordered stricter GLP-1 supply monitoring.
Context
The regulator issued advisories on March 10 and March 27, 2026. They told manufacturers and state controllers to stop surrogate ads and watch supply chains. States may now investigate ads and unauthorized sales.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked